Pneumocystis pneumonia in non-HIV patients

Cover Page

Cite item

Full Text

Abstract

The rates of pneumocystis pneumonia (PcP) are increasing in the HIV-negative susceptible population. Guidance for the diagnostic and treatment of PcP in patients with HIV, hematologic, and solid-organ transplant recipients is available Although for many other populations with immune disorders there remains an urgent need for recommendations. The main drug for treatment of PcP is trimethoprim/sulfamethoxazole. The possibilities of mycological diagnosis in routine clinical practice are very limited and require significant expansion. Outbreaks PcP in immunocompromised patients, likely caused by human-to-human spread, is highlighting the need for efficient infection control policies, sensitive diagnostic assays and Guidance for treatment in not-HIV patients.

About the authors

Vladimir B. Beloborodov

Russian Medical Academy of Continuous Professional Education

Email: vb_beloborodov@mail.ru
д-р мед. наук, проф. каф. инфекционных болезней Moscow, Russia

References

  1. Johnson N.M. Pneumonia in the acquired immune deficiency syndrome. Br Med J (Clin Res Ed) 1985; 290: 1299-301.
  2. Sepkowitz K.A. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34: 1098-107.
  3. Fei M.W, Sant C.A, Kim E.J et al. Severity and outcomes of Pneumocystis pneumonia in patients newly diagnosed with HIV infection: an observational cohort study. Scand J Infect Dis 2009; 41: 672-8.
  4. Iriat X, Challan Belval T, Fillaux J et al. Risk factors of Pneumocystis Pneumonia in Solid Organ recipients in the era of the common use of post transplantation prophylaxis. Am J Transplant 2015; 15: 190-9.
  5. White P.L, Backx M, Barnes R.A. Diagnosis and management of Pneumocystis jirovecii infection. Expert Rev Anti Infect Ther 2017; 15: 435-47.
  6. Iriart X, Bouar M.L, Kamar А, Berry A. Pneumocystis Pneumonia in Solid-Organ Transplant Recipients. J Fungi 2015; 1: 293-331.
  7. Liu Y, Su L, Jiang S.J, Qu H. Risk factors for mortality from Pneumocystis carinii pneumonia (PCP) in non-HIV patients: A meta-analysis. Oncotarget 2017; 8: 59729-39.
  8. Vanek J, Jirovec O. Parasitic pneumonia. Interstitial plasma cell pneumonia of premature, caused by Pneumocystis carinii. Zentralbl Bakteriol Parasitenkd Infektionskr Hyg 1952; 158: 120-7.
  9. Walzer P.D, Perl D.P, Krogstad D.J et al. Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med 1974; 80: 83-93.
  10. Jarboui M.A, Mseddi F, Sellami H et al. Pneumocystis: epidemiology and molecular approaches. Pathol Biol 2013; 61: 239-44.
  11. Waks A.G, Tolaney S.M, Galar A et al. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat 2015; 154: 359-67.
  12. Roux A, Canet E, Valade S et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerging Infect Dis 2014; 20: 1490-7.
  13. Sun J, Su J, Xie Y et al. Plasma IL-6/IL-10 ratio and IL-8, LDH, and HBDH level predict the severity and the risk of death in AIDS patients with Pneumocystis pneumonia. J Immunol Res 2016; 2016: 1583951-10.
  14. Antinori A, Maiuro G, Pallavicini F et al. Prognostic factors of early fatal outcome and long-term survival in patients with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome. Eur J Epidemiol 1993; 9: 183-9.
  15. Fernandez P, Torres A, Miro J.M et al. Prognostic factors influencing the outcome in pneumocystis carinii pneumonia in patients with AIDS. Thorax 1995; 50: 668-71.
  16. Dworkin M.S, Hanson D.L, Navin T.R. Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia, in the United States. J Infect Dis 2001; 183: 1409-12.
  17. Schmidt J, Lueck C, Ziesing S et al. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years. Critical Care 2018; 22: 307.
  18. Fillatre P, Decaux O, Jouneau S et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med 2014; 127: 1242.e11-7.
  19. Bienvenu A-L, Traore K, Plekhanova I et al. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. Int J Infect Dis 2016; 46: 11-7.
  20. Yu Q, Jia P, Su L et al. Outcomes and prognostic factors of non- HIV patients with pneumocystis jirovecii pneumonia and pulmonary CMV co-infection: a retrospective cohort study. BMC Infect Dis 2017; 17: 392.
  21. Kofteridis DP, Valachis A, Velegraki M et al. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients. J Infect Chemother 2014; 20: 412-6.
  22. Roblot F, Godet C, Le Moal G et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002; 21: 523-31.
  23. Datta S, Mahal S, Ravat V et al. Hospitalization Outcomes in Pneumocystis Pneumonia Inpatient Population: A Comparison between HIV and Non-HIV Patients. Cureus 2018; 10 (8): e3082.
  24. Guo F, Chen Y, Yang S-L et al. Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients: a retrospective study of two centers in China. PLoS One 2014; 9: e101943.
  25. Bitar D, Lortholary O, Le Strat Y et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerging Infect Dis 2014; 20: 1149-55.
  26. Rosen M.J, Clayton K, Schneider R.F et al. Intensive care of patients with HIV infection: utilization, critical illnesses, and outcomes. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155: 67-71.
  27. Boldt M.J, Bai T.R. Utility of lactate dehydrogenase vs radiographic severity in the differential diagnosis of Pneumocystis carinii pneumonia. Chest 1997; 111: 1187-92.
  28. White P.L, Price J.S, Backx M. Therapy and Management of Pneumocystis jirovecii Infection. J Fungi 2018; 4 (127): 266-86.
  29. Maini R, Henderson K.L, Sheridan E.A et al. Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg Infect Dis 2013; 19: 386-92.
  30. Pegorie M, Denning D.W, Welfare W. Estimating the burden of Invasive and Serious Fungal Disease in the United Kingdom. J Infect 2017; 74: 60-71.
  31. Buchacz K, Lau B, Jing Y et al. Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. J Infect Dis 2016; 214: 862-72.
  32. Williams K.M, Ahn K.W, Chen M et al. The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: A CIBMTR analysis. Bone Marrow Transplant 2016; 51: 573-80.
  33. Iriat X, Challan Belval T. Fillaux Jet al. Risk factors of Pneumocystis Pneumonia in Solid Organ recipients in the era of the common use of post transplantation prophylaxis. Am J Transplant 2015; 15: 190-9.
  34. Miller R.F, Le Noury J, Corbett E et al. Pneumocystis carinii infection: Current treatment and prevention. J Antimicrob Chemother 1996; 37: 33-53.
  35. Mu X-D, Jia P, Gao Li et al. Relationship between radiological stages and prognoses of Pneumocystis pneumonia in Non-AIDS immunocompromised patients. J Chin Med 2016; 129: 2020-5.
  36. White P.L, Backx M, Barnes R.A. Diagnosis and management of Pneumocystis jirovecii infection. Expert Rev Anti Infect Ther 2017; 15: 435-47.
  37. Vogel M.N, Brodoefel H, Hierl T et al. Differences and similarities of cytomegalovirus and Pneumocystis pneumonia in HIV-negative immunocompromised patients thin section CT morphology in the early phase of the disease. Br J Radiol 2007; 80: 516-23.
  38. Salzer H.J.F, Schäfer G, Hoenigl M et al. Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia. Respiration 2018; 96: 52-65.
  39. Vogel M.N, Weissgerber P, Goeppert B et al. Accuracy of serum LDH elevation for the diagnosis of Pneumocystis jiroveci pneumonia. Swiss Med Wkly 2011; 141: w13184.
  40. Nyamande K, Lalloo U.G. Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lund Dis 2006; 10: 510-5.
  41. Schildgen V, Mai S, Khalfaoui S et al. Pneumocystis jiroveci can be productively cultured in differentiated CuFi-8 airway cells. Mbio 2014; 5: E01186-14.
  42. Alanio A, Hauser P.M, Lagrou K et al. 5th European Conference on Infections in Leukemia (ECIL-5), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN). ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016; 71: 2386-96.
  43. Cruciani M, Marcati P, Malena M et al. Meta-analysis of diagnostic procedures for Pneumocystis carnii pneumonia in HIV-1-infected patients. Eur Respir J 2002; 20: 982-9.
  44. Summah H, Zhu Y-G, Falagas M.E et al. Use of real-time polymerase chain reaction for the diagnosis of Pneumocystis pneumonia in immuncompromised patients: A meta-analysis. J Chin Med 2013; 126: 1965-73.
  45. Fan L-C, Lu H-W, Cheng K-B et al. Evaluation of PCR in bronchoalveolar lavage fluid for diagnosis of Pneumocystis jirovecii pneumonia: A bivariate meta-analysis and systematic review. PLoS ONE 2013; 8: E73099.
  46. Sasso M, Chastang-Dumas E, Bastide S et al. Performances of four real-time PCR assays for the diagnosis of Pneumocystis jirovecii Pneumonia. J Clin Microbiol 2016; 54: 625-30.
  47. Karageorgopoulos D.E, Qu J.M, Korbila I.P et al. Accuracy of D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: A meta-analysis. Clin Microbiol Infect 2013; 19: 39-49.
  48. Onishi A, Sugiyama D, Kogata Y et al. Diagnostic Accuracy of Serum 1,3-D-Glucan for Pneumocystis jiroveci Pneumonia, Invasive Candidiasis, and Invasive Aspergillosis: Systematic Review and Meta-Analysis. J Clin Microbiol 2012; 50: 7-15.
  49. Li W.J, Guo YL, Liu T.J et al. Diagnosis of Pneumocystis pneumonia using serum (1-3)-D-Glucan:a bivariate meta-analysis and systematic review. Thorac Dis 2015; 7: 2214-25.
  50. Damiani C, Le Gal S, Da Costa C et al. Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1-3)-D-glucan for differential diagnosis of Pneumocystis pneumonia and Pneumocystis colonisation. J Clin Microbiol 2013; 51: 3380-8.
  51. Rose S.R, Vallabhajosyula S, Velez M.G et al. The utility of bronchoalveolar lavage -D-glucan testing for the diagnosis of invasive fungal infections. J Infect 2014; 69: 278-83.
  52. Salerno D, Mushatt D, Myers L et al. Serum and BAL-D-glucan for the diagnosis of Pneumocystis pneumonia in HIV positive patients. Respir Med 2014; 108: 1688-95.
  53. White P.L, Wingard J.R, Bretagne S et al. Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison with Antigen Testing. Clin Infect Dis 2015; 61: 1293-303.
  54. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf
  55. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. https://aidsetc.org/disclaimer
  56. Martin S.I, Fishman J.A, The AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in Solid organ transplantation. Am J Translant 2013; 13: 272-9.
  57. Cushion M.T, Collins M.S. Susceptibility of Pneumocystis to echinocandins in suspension and biofilm cultures. Antimicrob Agents Chemother 2011; 55: 4513-8.
  58. Wang L.I, Liang H, Ye L.I et al. Adjunctive corticosteroids for the treatment of Pneumocystis jiroveci pneumonia in patients with HIV: A meta-analysis. Exp Ther Med 2016; 11: 683-7.
  59. Iriart X, Bouar M.L, Kamar N, Berry A. Pneumocystis Pneumonia in Solid-Organ Transplant Recipients. J Fungi 2015; 1: 293-331.
  60. Kosaka M, Ushiki A, Ikuyama Y et al. A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection. Antimicrob. Agents Chemother 2017; 61.
  61. Suárez I, Roderus L, van Gumpel E et al. Low prevalence of DHFR and DHPS mutations in Pneumocystis jirovecii strains obtained from a German cohort. Infection 2017; 45: 341-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».